Biogen Ma Inc.

Biogen Idec Ma Inc.

Sunesis Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Millenium Pharmaceuticals, Inc.

Boigen Ma Inc.

Kevin Guckian

Gnanasambandam Kumaravel

Bin Ma

Edward Yin-Shiang Lin

Jermaine Thomas

Arthur G Taveras

Guo Zhu Zheng

Richard Dana Caldwell

Lei Zhang

Zhili Xin

Xiaogao Liu

Lihong Sun

Sha Mi

Wen-Cherng Lee

Daniel M Scott

Timothy Raymond Chan

Zhan Shi

Hairuo Peng

Jeffrey Vessels

Edward Yin Shiang Lin

Nathan Genung

Deping Wang

Zhaohui Shao

Ryan Gianatassio

Daniel A Erlanson

Joseph P Lyssikatos

Brian Stuart Lucas

Tracy J Jenkins

Robert Meissner

Irina Leaf

Jeremy Duffield

Thinh Nguyen

Robert Lowell Simmons

Stig Hansen

Kathy Jingyuan Cao

Joseph Arndt

Jeffery Vessels

Kurt D Van Vloten

Nuzhat Pathan

Kenneth Egnard Lind

Bradley T Tangonan

Patrick R Conlon

Jianhua Chao

Charles Jewell

Daniel Erlanson

Ma Bin

Edward Lin

Kurt Van Vloten

Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R, R, R, Y, Y, and Z are as defined herein.

Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R, R, R, Y, Y, m, n, and p are as defined herein.

Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R, R, R, Y, Y, Ar, Z and n are as defined herein.

O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Described herein are compounds represented by formula (I&#x2033;) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, R, R, m, n, Y, Y, Rand Rare defined herein.

O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease. 

IRAK4 inhibiting agents

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

S1P modulating agents

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

SIP modulating agents

Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

Compounds that are S1P modulating agents and/or ATX modulating agents

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Heterobicyclic sphingosine 1-phosphate analogs

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Heterocyclic compounds useful as PDK1 inhibitors

Growing community of inventors

Northborough, MA, United States of America

Kevin Guckian